vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and TON Strategy Co (TONX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $5.7M, roughly 1.6× TON Strategy Co). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -3968.6%, a 3908.2% gap on every dollar of revenue. On growth, TON Strategy Co posted the faster year-over-year revenue change (694.2% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-8.0M). Over the past eight quarters, TON Strategy Co's revenue compounded faster (46.1% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
PLX vs TONX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $5.7M |
| Net Profit | $-5.5M | $-227.9M |
| Gross Margin | 49.4% | 64.3% |
| Operating Margin | -51.1% | -159.2% |
| Net Margin | -60.3% | -3968.6% |
| Revenue YoY | -49.9% | 694.2% |
| Net Profit YoY | -184.8% | -7047.9% |
| EPS (diluted) | $-0.06 | $-3.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $5.7M | ||
| Q3 25 | $17.9M | $3.6M | ||
| Q2 25 | $15.7M | $2.1M | ||
| Q1 25 | $10.1M | $1.3M | ||
| Q4 24 | $18.2M | $723.0K | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $13.5M | — | ||
| Q4 23 | $10.5M | — |
| Q4 25 | $-5.5M | $-227.9M | ||
| Q3 25 | $2.4M | $84.3M | ||
| Q2 25 | $164.0K | $-2.4M | ||
| Q1 25 | $-3.6M | $-2.6M | ||
| Q4 24 | $6.5M | $-3.2M | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $-2.2M | — | ||
| Q4 23 | $-6.0M | — |
| Q4 25 | 49.4% | 64.3% | ||
| Q3 25 | 53.4% | 75.4% | ||
| Q2 25 | 62.5% | 71.2% | ||
| Q1 25 | 19.1% | 73.4% | ||
| Q4 24 | 78.7% | 81.5% | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q4 23 | 15.5% | — |
| Q4 25 | -51.1% | -159.2% | ||
| Q3 25 | 11.9% | -601.5% | ||
| Q2 25 | 7.5% | -138.2% | ||
| Q1 25 | -41.0% | -203.8% | ||
| Q4 24 | 39.6% | -513.1% | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -18.0% | — | ||
| Q4 23 | -53.5% | — |
| Q4 25 | -60.3% | -3968.6% | ||
| Q3 25 | 13.2% | 2336.8% | ||
| Q2 25 | 1.0% | -111.9% | ||
| Q1 25 | -35.8% | -196.5% | ||
| Q4 24 | 35.6% | -440.9% | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | -16.4% | — | ||
| Q4 23 | -57.6% | — |
| Q4 25 | $-0.06 | $-3.89 | ||
| Q3 25 | $0.03 | $2.23 | ||
| Q2 25 | $0.00 | $-1.79 | ||
| Q1 25 | $-0.05 | $-2.51 | ||
| Q4 24 | $0.10 | $10.41 | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q4 23 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $39.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $406.5M |
| Total Assets | $82.3M | $411.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $39.5M | ||
| Q3 25 | $13.6M | $53.9M | ||
| Q2 25 | $17.9M | $10.4M | ||
| Q1 25 | $19.5M | $12.2M | ||
| Q4 24 | $19.8M | $12.5M | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q4 23 | $23.6M | — |
| Q4 25 | $48.2M | $406.5M | ||
| Q3 25 | $52.9M | $639.1M | ||
| Q2 25 | $49.9M | $19.4M | ||
| Q1 25 | $45.2M | $14.6M | ||
| Q4 24 | $43.2M | $16.2M | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $28.6M | — | ||
| Q4 23 | $33.6M | — |
| Q4 25 | $82.3M | $411.2M | ||
| Q3 25 | $82.3M | $661.9M | ||
| Q2 25 | $78.5M | $23.7M | ||
| Q1 25 | $73.9M | $18.4M | ||
| Q4 24 | $73.4M | $20.6M | ||
| Q3 24 | $61.6M | — | ||
| Q2 24 | $91.5M | — | ||
| Q4 23 | $84.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-8.0M |
| Free Cash FlowOCF − Capex | $1.6M | $-8.0M |
| FCF MarginFCF / Revenue | 17.8% | -139.3% |
| Capex IntensityCapex / Revenue | 4.4% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-20.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-8.0M | ||
| Q3 25 | $-3.7M | $-9.4M | ||
| Q2 25 | $-5.2M | $-2.3M | ||
| Q1 25 | $-5.1M | $-1.1M | ||
| Q4 24 | $4.0M | $-1.9M | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $-3.6M | — | ||
| Q4 23 | $3.6M | — |
| Q4 25 | $1.6M | $-8.0M | ||
| Q3 25 | $-4.2M | $-9.4M | ||
| Q2 25 | $-5.7M | $-2.3M | ||
| Q1 25 | $-5.4M | $-1.1M | ||
| Q4 24 | $3.6M | $-2.0M | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q4 23 | $3.3M | — |
| Q4 25 | 17.8% | -139.3% | ||
| Q3 25 | -23.7% | -261.4% | ||
| Q2 25 | -36.2% | -107.8% | ||
| Q1 25 | -53.0% | -87.0% | ||
| Q4 24 | 19.6% | -279.9% | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q4 23 | 31.9% | — |
| Q4 25 | 4.4% | 0.1% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 2.8% | 0.1% | ||
| Q1 25 | 3.0% | 5.1% | ||
| Q4 24 | 2.3% | 22.1% | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q4 23 | 2.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | -0.11× | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TONX
| Market Live | $4.8M | 83% |
| Other | $960.0K | 17% |
